To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Electroconvulsive therapy (ECT) may be accompanied by amnesia. However, the extent to which different memory subtypes are affected is unclear, as well-controlled longitudinal studies are sparse. We aimed to investigate short- and long-term effects of ECT on different aspects of memory.
Methods
We recruited patients with depression referred to ECT (n = 31) or other treatment (n = 21) and healthy participants (n = 29). We measured autobiographical (Columbia Autobiographical Memory Interview – Short Form), verbal (Verbal Learning Test – Delayed), and visual (Rey Complex Figure Test) anterograde memory at baseline (T1), post-ECT (T2), and 6-month follow-up (T3). We performed a repeated measures mixed ANOVA for each outcome. An ANCOVA explored whether age and cognitive reserve were associated with severity of amnesia. ClinicalTrials.gov: NCT04160286.
Results
A substantial effect of ECT on autobiographical memory was indicated by a group-by-time interaction, F (3.45, 103.51) = 22.261, p < 0.001, partial η2 = 0.426. The effect remained stable, and inferior to control groups, at T3 (p < 0.001). A large effect of ECT on verbal anterograde memory was suggested by a group-by-time interaction, F (2, 68) = 6.138, p = 0.004, partial η2 = 0.153, reflecting transient impairment after ECT (p = 0.009). No ECT-related decline in visual anterograde memory was observed (p = 1.0). Neither age nor cognitive reserve was associated with degree of amnesia.
Conclusions
Our findings suggest that ECT may be associated with autobiographical amnesia, potentially lasting at least 6 months, and transient verbal, but not visual, anterograde amnesia.
The excitation–inhibition (E/I) imbalance is a major pathological characteristic of major depressive disorder (MDD). However, whether/how electroconvulsive therapy (ECT) modulates neuronal homeostasis or E/I balance in MDD and its molecular basis is still largely unknown.
Methods
In this study, longitudinal rs-fMRI data from 46 patients with MDD receiving ECT and 46 healthy controls were included. The Hurst index was used to characterize the E/I balance, and mixed-effects model was constructed to assess the interactive effects of ECT on the Hurst index and functional connectivity (FC). Moreover, spatial correlation analyses were conducted by integrating cortical myelination pattern, glucose metabolism distribution, neurotransmitter density maps, and transcriptomic data to reveal the underlying molecular basis.
Results
ECT significantly reduces the Hurst index in the middle cingulate cortex (MCC) and induces functional decoupling between the MCC and the posterior cingulate cortex. Furthermore, changes in the Hurst index were closely associated with cortical myelination, glucose metabolism, and the distribution maps of dopamine and histamine. Spatial transcriptomic association analysis revealed that genes regulating the effects of ECT on Hurst index or FC are specifically enriched in cell types such as excitatory neurons, astrocytes, and oligodendrocytes, and are primarily involved in biological processes including synaptic signal transduction, neuronal projection regulation, and glutamatergic synapses.
Conclusion
These findings suggest that ECT may regulate the processes of myelin remodelling through neurons and glial cells by influencing the expression levels of relevant genes, thereby modulating the E/I balance and functional network activity in a synergistic manner to improve depressive symptoms.
Electroconvulsive therapy (ECT) is an established treatment for schizophrenia. Oxidative stress has been implicated in its pathophysiology, and Thiobarbituric acid reactive substances (TBARS) are widely used markers of lipid peroxidation. However, the effect of ECT on TBARS levels remains unclear.
Aims:
To compare changes in TBARS levels in schizophrenia inpatients receiving ECT plus pharmacotherapy versus pharmacotherapy alone and to examine associations between TBARS levels and clinical variables.
Method:
Thirty-eight inpatients with schizophrenia were included (ECT + pharmacotherapy: n = 18; pharmacotherapy only: n = 20). Serum TBARS levels were measured at admission and discharge. Clinical severity was assessed using the Clinical Global Impression and Positive and Negative Syndrome Scale. Non-parametric analyses and multiple linear regression were conducted.
Results:
TBARS levels did not significantly change from admission to discharge in either the ECT group (median 756.5 vs. 768.5 nmol/L) or the pharmacotherapy group (median 644.0 vs. 693.5 nmol/L). Percentage changes were comparable between groups (9.64% vs. 15.34%). TBARS levels were negatively correlated with age (ρ = −0.441) and illness duration (ρ = −0.333). Regression analysis showed that suicide history was the only significant predictor of TBARS levels (β = −0.402), while treatment modality was not associated with TBARS change.
Conclusions:
ECT was not associated with statistically significant changes in TBARS levels; however, these findings should be interpreted cautiously given the exploratory nature of the study, the small sample size, and methodological limitations. The observed associations with clinical variables suggest that oxidative stress markers may have relevance in specific patient subgroups, warranting further investigation.
Age at onset of depression is linked to clinical presentation and outcome, but its relevance for electroconvulsive therapy (ECT) remains unclear. We examined whether age at onset of first depressive episode requiring hospitalization predicts ECT response and remission, and whether onset age reflects distinct clinical profiles.
Methods
A nationwide register-based study, including 14,141 patients who received an index ECT series for a depressive episode in Sweden during 2008–2021, with outcome data in the Swedish Quality Register for ECT. Response was “very much/much improved” on the Clinical Global Impression – Improvement scale, and remission was a post-treatment Montgomery-Åsberg Depression Rating Scale-Self report score of 10 or less. Hierarchical logistic regression and causal mediation analyses examined associations of age at onset (early, mid, late), chronological age, baseline severity, psychotic symptoms, and somatic and psychiatric comorbidity with outcome and their mediating role.
Results
Response and remission rates were highest in late-onset depression (84.9%, 60.2%) and lowest in early-onset depression (64.6%, 26.3%). Later onset and older age were independently associated with higher odds of both outcomes, but the onset-age association attenuated substantially after adjustment. The early-onset disadvantage operated mainly through psychiatric comorbidity and treatment complexity, and the late-onset advantage was driven by psychotic features. Associations of age, male sex, and psychotic symptoms with response differed by onset group.
Conclusions
Age of onset of first depressive episode requiring hospitalization was associated with clinical profiles and ECT outcomes, independent of chronological age, suggesting early- and late-onset depression are partly distinct subtypes relevant to treatment planning.
Electroconvulsive therapy (ECT) is a safe and effective medical treatment, yet provision varies internationally. We provide an up-to-date review of ECT practice in Nordic and western European countries.
Methods
European experts contributed data from peer-reviewed literature, governmental publications, unpublished administrative datasets, and hitherto unpublished surveys. The primary outcome was the number of individuals treated with ECT in each country per year. Primary analysis compared the annual treated person rate per million population in the most recent year since 2015 for which data were available. Secondary analysis compared trends in rates over 25 years, in countries for which a reliable outcome was available at two or more time points.
Results
Across 15 countries, 12 had data meeting primary analysis criteria. Of these, all Nordic countries had annual treated patient rates per million population over 200, Italy 2.7, and other western European countries between 30 and 100. German-, Dutch-, and French-speaking countries saw increases in ECT use over 25 years, while English-speaking countries exhibited declines. Unilateral placement varied from 16% of treatments in the United Kingdom to 79% in Norway. Everywhere, most ECT was given for depressive episodes.
Conclusions
Although the optimal rate of use is unknown, widely differing rates across European nations suggest ECT is underused in some high-income countries, depriving patients of vital medical care. The European ECT community must support the development of reliable data collection on usage across the continent and service improvement where provision is underdeveloped, to ensure appropriate treatment is offered to all patients for whom it is indicated.
Belz and colleagues present GREAT, a seven-item clinical instrument for predicting electroconvulsive therapy response in unipolar depression, with promising discriminatory validity (AUC 0.841). We identify three methodological gaps – absent calibration, limited sample representativeness and unquantified incremental value – that must be addressed before GREAT can guide individual clinical decisions.
To evaluate the real-world effectiveness of electroconvulsive therapy (ECT) in schizophrenia and schizoaffective disorder, and to identify clinical predictors of response. We conducted a naturalistic study using routinely collected data from the Scottish ECT Accreditation Network between 2009 and 2018. Individuals with schizophrenia or schizoaffective disorder who had complete pre- and post-treatment Clinical Global Impression ratings were included. Clinical improvement and associations with demographic and clinical variables were examined.
Results
A total of 153 patients were included (94 with schizophrenia, 59 with schizoaffective disorder). Overall, 86% showed clinical improvement following ECT. Marked improvement (‘much’ or ‘very much improved’) was observed in 65% of patients with schizophrenia and in 78% with schizoaffective disorder. In schizophrenia, younger age, greater baseline depressive symptoms and receipt of emergency treatment were associated with higher likelihood of improvement.
Clinical implications
These findings indicate robust effectiveness of ECT for schizophrenia and schizoaffective disorder in routine National Health Service practice and highlight clinically relevant predictors of response, suggesting that current guideline positions may warrant re-evaluation.
Electroconvulsive therapy (ECT) is an established intervention for severe or treatment-resistant psychiatric illnesses, including depression, schizophrenia, mania and catatonia. Despite its efficacy, concerns over its risks have contributed to ongoing stigma and hesitancy regarding its use. Traditional clinical trials have demonstrated the superiority of ECT in symptom reduction compared with other treatments, yet are impractical for assessing rare or long-term outcomes. Observational studies using administrative health data can assess rare or long-term outcomes, but are limited by confounding/bias. This review synthesises evidence from studies utilising administrative health data and modern statistical methods to address clinically relevant questions about ECT’s association with (a) dementia, (b) major adverse cardiovascular/cerebrovascular events, (c) suicide deaths and (d) all-cause mortality. Most studies indicate that, after adjusting for confounding, ECT does not increase the risk of dementia or major adverse cardiovascular/cerebrovascular events. Furthermore, ECT is likely associated with a substantial reduction in suicide mortality and all-cause mortality. Although observational studies cannot fully eliminate unmeasured confounding, the consistency of the findings from diverse investigators and congruence with clinical trials and neuroimaging studies lends support to their validity. These modern observational studies have yielded results that reinforce ECT’s safety and efficacy supporting its position as a life-saving treatment.
The chapter opens by exploring different perspectives on defining mental disorders, contrasting Freudian psychoanalytic views with the diagnostic criteria of the DSM and newer alternative frameworks for understanding mental health. It then critiques early modular models of emotion, such as Papez’s circuit and the limbic system, which attempt to localize emotions to specific brain regions but fail to comprehensively explain diverse emotions and their complex manifestations in behavior. The chapter concludes by evaluating the value and limitations of brain stimulation for treating depression, with a focus on modern experiments involving deep-brain stimulation.
Electroconvulsive therapy (ECT) is an effective treatment of severe manifestations of mental illness. Since delay in initiation of ECT can have detrimental effects, prediction of the need for ECT could improve outcomes via more timely treatment initiation. Therefore, this study aimed to predict the need for ECT following admission to a psychiatric hospital.
Methods:
This study was based on electronic health record (EHR) data from routine clinical practice. Adult patients admitted to a hospital within the Psychiatric Services of the Central Denmark Region between January 2013 and November 2021 were included in the study. The outcome was initiation of ECT >7 days (to not include patients admitted for planned ECT) and ≤67 days after admission. The data was randomly split into an 85% training set and a 15% test set. On the 7th day of the inpatient stay, machine learning models (extreme gradient boosting (XGBoost)) were trained to predict initiation of ECT and subsequently tested on the test set.
Results:
The cohort consisted of 41,610 patients with 164,961 admissions. In the held out test set, the trained model predicted ECT initiation with an area under the receiver operating characteristic curve of 0.94, 47% sensitivity, 98% specificity, positive predictive value (PPV) of 24% and negative predictive value (NPV) of 99%. The top predictors were the highest suicide assessment score and mean Brøset violence checklist score in the preceding three months.
Conclusions:
EHR data from routine clinical practice may be used to predict need for ECT. This may lead to more timely treatment initiation.
Electroconvulsive therapy (ECT) is considered among the safest and most effective treatments for mental disorders. In Nepal, ECT is practised but data regarding its use, techniques and protocols are limited. The use of non-modified ECT in Nepal is also debatable concerning ethical issues and its outcomes.
Aims
To explore the characteristics of ECT practice, its availability in psychiatric services and to determine the standards and techniques of ECT practice in Nepal.
Method
A cross-sectional, descriptive study via an online survey with a questionnaire was used. All hospitals providing in-patient psychiatric services in Nepal were included in the study. Data were collected using Google Forms with a URL link. Questionnaires were sent to the psychiatrist at each facility. Ethical approval was obtained from Nepal Health Research Council (reference no. 2352).
Results
Of 32 centres, 31 responded (96.9%). ECT practice was employed in 23 (74.2%) of these; 14 (60.9%) had a written ECT protocol and 95.7% obtained written family consent. Pre-ECT work-up was performed in all cases. Brief-pulse devices were used in 81.8% (n = 18), with bitemporal placement being most common. Modified ECT was practised in 16 (69.6%) centres; 4 (17.4%) used both modified and unmodified ECT and 3 (13%) used only unmodified ECT – mainly due to lack of either equipment or an anaesthesiologist. Propofol (82.8%, n = 18) and ketamine (31.8%, n = 7) were the most commonly used anaesthetics, and all centres used succinylcholine for modified ECT. Catatonia (95.7%, n = 22) was recorded as the most common indication.
Conclusions
This nationwide survey shows that ECT is widely used in Nepal, mainly in the form of modified bitemporal ECT, although some centres are still relying on unmodified ECT due to limited resources.
Suicide and self-harm in people with depression are major public health concerns; electroconvulsive therapy (ECT) is a treatment recommended in UK clinical guidelines for severe mood disorders. We aimed to investigate published literature on the effect of ECT on the incidence of suicide, self-harm, and the recorded presence of suicidal thoughts (suicide-related outcomes). We hypothesized that ECT would be associated with a reduced incidence of suicide-related outcomes and all-cause mortality. We reviewed systematically all eligible studies as specified in our protocol (PROSPERO 293393). We included studies that compared ECT against a comparator treatment, and which included suicide-related outcomes or mortality. We searched Medline, EMBASE, and PsycINFO on January 24, 2022, updated to February 12, 2025. We identified 12,313 records and, after deduplication, screened 8,281 records on title and abstract and 212 on full-text, identifying 17 eligible studies. Studies showed significant heterogeneity in methodology, outcomes, time points chosen, and study populations. Three included studies investigated change in the suicidality domain on psychological rating scales: two showed a reduction in the ECT group; the other was underpowered for this outcome. Meta-analysis of suicide outcomes showed significant statistical heterogeneity and did not detect differences in a consistent direction. Meta-analysis of other mortality outcomes showed reductions in the risk of all-cause mortality (log relative risk [logRR]: −0.29; 95% CI: −0.53, −0.05) and non-suicide mortality (logRR: −0.21; 95% CI: −0.35, −0.07). Further high-quality studies are needed, which should seek to minimize biases (particularly confounding by indication) and report a wider range of suicide-related outcomes.
Electroconvulsive therapy (ECT) is one of the most effective treatments for depression, but worries about cognitive side effects remain. This retrospective study evaluated cognitive outcomes and the antidepressant efficacy of ECT in a real-life sample of patients with treatment-resistant uni- or bipolar depression.
Methods
We included 90 depressed inpatients aged 49 ± 13.8 (SD) years who underwent 10 ± 2.1 (SD) unilateral or bitemporal ECT treatments and completed an extensive pre- and post-treatment psychological test battery. The Hamilton Depression Rating Scale (HAMD) and the Mini-Mental State Examination (MMSE) were evaluated as main outcomes pre-/post-ECT treatment.
Results
There was no significant change in MMSE scores between pre-/post-treatment assessments (β = 0.10, 95% confidence interval [CI] [−0.44, 0.25], p = 0.58), indicating no negative effect on global cognition. A minority of patients (N = 3) experienced a reduction of ≥5 points in the MMSE. Most cognitive tests showed no difference; however, some domains revealed statistically significant improvements (visual learning and motoric reaction time), whereas one domain showed a significant decline (verbal learning). Higher age and higher stimulus doses predicted worse outcomes in some cognitive domains. While ECT significantly reduced depressive symptoms measured by HAMD (β = −5.51, 95% CI [−7.08, −3.94], p < 0.001), depressive symptoms were not associated with cognitive outcomes.
Conclusions
No major cognitive changes were observed. While test results indicated deterioration in verbal learning and improvement in visual learning and motoric reaction time, effect sizes were small, and other cognitive tests showed no significant changes. The main limitation is the absence of retrograde memory assessment.
Howard CH Khoe, National Psychiatry Residency Programme, Singapore,Cheryl WL Chang, National University Hospital, Singapore,Cyrus SH Ho, National University Hospital, Singapore
Chapter 36 covers the topic of catatonia and electroconvulsive therapy . Through a case vignette with topical MCQs for consolidation of learning, readers are brought through the management of a patient with catatonia from first presentation to subsequent complications of the conditions and its treatment with electroconvulsive therapy (ECT) and other medications. Things covered include the symptoms, diagnosis, differential diagnoses, investigations, the evidence-based use and indications of pharmacological treatment such as benzodiazpines and ECT, adverse effects of ECT, management of adverse cognitive effects from ECT and use of ECT in pregnancy.
Howard CH Khoe, National Psychiatry Residency Programme, Singapore,Cheryl WL Chang, National University Hospital, Singapore,Cyrus SH Ho, National University Hospital, Singapore
Chapter 3 covers the topic of major depressive disorder. Through a case vignette with topical MCQs for consolidation of learning, readers are brought through the management of a patient with major depressive disorder from first presentation to subsequent complications of the conditions and its treatment. Things covered include the symptoms, psychopathology, co–morbid conditions, psychological therapies, the evidence-based use of pharmacological treatment including antidepressants and adjuncts, adverse effects of commonly used medications, management of treatment-resistant depression.
Relapse following electroconvulsive therapy (ECT) remains a significant clinical challenge despite continuation of pharmacotherapy. We performed a systematic review and meta-analysis (PROSPERO CRD420251000113) of the efficacy and acceptability of continuation ECT (cECT) combined with pharmacotherapy compared to pharmacotherapy alone for relapse prevention following an acute course of ECT for depression. We searched PubMed, Embase, Web of Science, and CENTRAL databases for randomized controlled trials enrolling adults diagnosed with a unipolar or bipolar major depressive episode, who met remission or response criteria after an acute course of ECT and who were subsequently randomized to cECT with pharmacotherapy versus pharmacotherapy alone. The efficacy outcome was the cumulative relapse rate at 6-month follow-up. Data were synthesized using random-effects meta-analyses with effect sizes expressed as relative risks (RRs) with 95% confidence intervals (CIs). Four trials (n = 254) met the inclusion criteria. cECT combined with pharmacotherapy significantly reduced relapse compared to pharmacotherapy alone (RR = 0.57, 95% CI = 0.37–0.88; I2 = 0%; number needed to treat = 7). Sensitivity analyses consistently supported the superiority of cECT under all examined dropout scenarios and analytic approaches. Acceptability, measured by all-cause dropout, was similar between the groups (RR = 1.12; 95% CI = 0.48–2.62; I2 = 0%). cECT combined with pharmacotherapy significantly reduces the RR of relapse by 43% compared to pharmacotherapy alone without compromising acceptability. These findings reinforce the role of cECT as a valuable relapse prevention strategy following successful acute ECT and highlight the need for larger, multicenter trials to further optimize post-ECT prophylaxis.